Functional Defects and the Influence of Age on the Frequency of CD4+CD25+ T-Cells in Type 1 Diabetes
- Todd M. Brusko1,
- Clive H. Wasserfall1,
- Michael J. Clare-Salzler1,
- Desmond A. Schatz2 and
- Mark A. Atkinson1
- 1Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida
- 2Department of Pediatrics, University of Florida, Gainesville, Florida
- Address correspondence and reprint requests to Mark A. Atkinson, PhD, Department of Pathology, College of Medicine, University of Florida, ARB-R3-128, 1600 SW Archer Rd., Gainesville, FL 32610-0275. E-mail: atkinson{at}ufl.edu
Abstract
CD4+CD25+ T-cells appear to play a crucial role in regulating the immune response. Therefore, we evaluated the peripheral blood frequency and function of CD4+CD25+ T-cells in 70 type 1 diabetic patients and 37 healthy individuals. Interestingly, a positive correlation was observed between increasing age and CD4+CD25+ T-cell frequency in both subject groups. In contrast to previous studies of nonobese diabetic mice and type 1 diabetic patients, similar frequencies of CD4+CD25+ and CD4+CD25+Bright T-cells were observed in healthy control subjects and type 1 diabetic patients of similar age. There was no difference between type 1 diabetic subjects of recent-onset versus those with established disease in terms of their CD4+CD25+ or CD4+CD25+BrightT-cell frequency. However, type 1 diabetic patients were markedly defective in their ability to suppress the proliferation of autologous effector T-cells in vitro. This type 1 diabetes-associated defect in suppression was associated with reduced production of interleukin (IL)-2, γ-interferon, and transforming growth factor-β, whereas other cytokines including those of adaptive and innate immunity (IL-10, IL-1β, IL-6, IL-8, IL-12p70, and tumor necrosis factor-α) were similar in control subjects and type 1 diabetic patients. These data suggest that age strongly influences the frequency of CD4+CD25+ T-cells and that function, rather than frequency, may represent the means by which these cells associate with type 1 diabetes in humans.
- APC, allophycocyanin
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- IFN-γ, γ-interferon
- IL, interleukin
- PE, phycoerythrin
- Teff, CD4+CD25− effector T-cell
- TGF, transforming growth factor
- TNF, tumor necrosis factor
- Treg, CD4+CD25+ regulatory T-cell
Footnotes
-
- Accepted February 9, 2005.
- Received October 20, 2004.
- DIABETES














